August 2015, the U.S. Food and Drug Administration approved
the medication flibanserin (Addyi) for use in premenopausal
women with hypoactive sexual desire disorder.
then, some researchers have questioned its efficacy and
safety, claiming the side effects may not be worth it.
Jordan Rullo of the Mayo Clinic Women’s Health Clinic is a
member of the International Society for the Study of Women’s
Sexual Health. She and her colleagues support the use of the
drug for the subset of women who benefit from it.
recent meta-analysis on flibanserin puts into question its
efficacy and safety, but this analysis has several
flaws," Rullo says. "Because of these flaws, in my
opinion, the findings of this meta-analysis do not change what
we already know about the safety and efficacy of flibanserin."
explanation, visit the International Society for the Study of
Women’s Sexual Health website at http://bit.ly/1pina61.
the clinical trials that tested the safety and efficacy of
flibanserin, researchers looked at three things: self-reported
increase in desire, more sexually satisfying events and levels
of sexual distress. Results showed a modest benefit. Rullo
says that for this group, the medication increased
self-reported sexual desire, increased the number of
satisfying sexual events and decreased self-reported stress.